Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis

Journal of Clinical Investigation

Volumn 112, Issue 4, 2003, Pages 517-526

  Tolosa, Eva ^a   Li, Weijie ^b   Yasuda, Yoshiyuki ^b   Wienhold, Wolfgang ^a   Denzin, Lisa K ^c   Lautwein, Alfred ^a   Driessen, Christoph ^a   Schnorrer, Petra ^a   Weber, Ekkehard ^d   Stevanovic, Stefan ^a   Kurek, Raffael ^a   Melms, Arthur ^a   Brömme, Dieter ^b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN; CATHEPSIN L; CATHEPSIN S; CATHEPSIN V; CLASS II ASSOCIATED INVARIANT CHAIN PEPTIDE; CYSTEINE PROTEINASE; PROTEIN; UNCLASSIFIED DRUG; B LYMPHOCYTE ANTIGEN; HLA ANTIGEN CLASS 2; MESSENGER RNA; PEPTIDE; RECOMBINANT PROTEIN;

ANTIGEN BINDING; ARTICLE; COMPLEX FORMATION; ENZYME ACTIVE SITE; EPITHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; INVARIANT CHAIN; MYASTHENIA GRAVIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYMUS; ADOLESCENT; ANIMAL; CHEMISTRY; CHILD; DOSE RESPONSE; IMMUNOHISTOCHEMISTRY; INFANT; LASER; METABOLISM; MOUSE; NEWBORN; PHYSIOLOGY; PRESCHOOL CHILD; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE DISTRIBUTION; WESTERN BLOTTING;

ADOLESCENT; ANIMALS; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; BLOTTING, WESTERN; CATHEPSINS; CHILD; CHILD, PRESCHOOL; CYSTEINE ENDOPEPTIDASES; DOSE-RESPONSE RELATIONSHIP, DRUG; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; INFANT, NEWBORN; LASERS; MICE; MYASTHENIA GRAVIS; PEPTIDES; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THYMUS GLAND; TISSUE DISTRIBUTION;

EID: 0141831692     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200318028     Document Type: Article

References (40)

1. Riese, R.J., and Chapman, H.A. 2000. Cathepsins and compartmentalization in antigen presentation. Curr. Opin. Immunol. 12:107-113.
2. Villadangos, J.A., and Ploegh, H.L. 2002. Proteolysis in MHC class II antigen presentation who's in charge? Immunity. 12:233-239.
3. Manoury, B., et al. 1998. An asparaginyl endopepridase processes a microbial antigen for class II MHC presentation [see comments]. Nature. 396:695-699.
4. Driessen, C., Lennon-Dumenil, A.M., and Ploegh, H.L. 2001. Individual cathepsins degrade immune complexes internalized by antigenpresenting cells via Fcgamma receptors. Eur J. Immunol. 31:1592-1601.
5. Cresswell, P. 1994. Assembly, transport, and function of MHC class II molecules. Annu. Rev. Immunol. 12:259-293.
6. Malcherek, G., Gnau, V., Jung, G., Rammensee, H.G., and Melms, A. 1995. Supermotifs enable natural invariant chain-derived peptides to interact with many major histocompatibility complex-class II molecules. J. Exp. Med. 181:527-536.
7. Robbins, N.F., Hammond, C., Denzin, L.K., Pan, M., and Cresswell, P. 1996. Trafficking of major histocompatibility complex class II molecules through intracellular compartments containing HLA-DM. Hum. Immunol 45:13-23.
8. Riese, R.J., et al. 1998. Cathepsin S activity regulates antigen presentation and immunity. J. Clin. Invest. 101:2351-2363.
9. Denzin, L.K., and Cresswell, P. 1995. HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers and facilitates peptide loading. Cell. 82:155-165.
10. Riese, R.J., et al. 1996. Essential role for cathepsin S in MHC class II associated invariant chain processing and peptide loading, Immunity. 4:357-366.
11. Nakagawa, T.Y., et al. 1999. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity. 10:207-217.
12. Shi, G.P., et al. 2000. Role for cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages. J. Exp. Med. 191:1177-1186.
13. Nakagawa, T., et al. 1998. Cathepsin L: critical role in li degradation and CD4 T cell selection in the thymus. Science. 280:450-453.
14. Bromme, D., Li, Z., Barnes, M., and Mehler, E. 1999. Human cathepsin V functional expression, tissue distribution, electrostatic surface potential, enzymatic characterization, and chromosomal localization. Biochemistry. 38:2377-2385.
15. Santamaria, I., et al. 1998. Cathepsin L2, a novel human cysteine proteinase produced by breast and colorectal carcinomas. Cancer Res. 58:1624-1630.
16. Itoh, R., Kawamoto, S., Adachi, W., Kinoshita, S., and Okubo, K. 1999. Genomic organization and chromosomal localization of the human cathepsin L2 gene. DNA Res. 6:137-140.
17. Schroter, C.J., et al. 1999. A rapid method to separate endosomes from lysosomal contents using differential centrifugation and hyporonic lysis of lysosomes. J. Immunol. Methods. 227:161-168.
18. Bromme, D., and McGrath, M.E. 1996. High level expression and crystallization of recombinant human cathepsin S. Protein Sci. 5:789-791.
19. Barrett, A.J., et al. 1982. L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. Biochem. J. 201:189-198.
20. Weber, E., Bahn, H., and Gunther, D. 1997. Monoclonal antibodies against cathepsin L and procathepsin L of different species. Hybridoma. 16:159-166.
21. Nissler, K., et al. 1999. The half-life of human procathepsin S. Eur. J. Biochem. 263:717-725.
22. Greenbaum, D., Medzihradszky, K.F., Burlingame, A., and Bogyo, M. 2000. Epoxide electrophiles as activity-dependent cysteine protease profiling and discovery tools. Chem. Biol. 7:569-581.
23. Machamer, C.E., and Cresswell, P. 1984. Monensin prevents terminal glycosylation of the N- and O-linked oligosaccharides of the HLA-DR-associated invariant chain and inhibits its dissociation from the alphabeta chain complex. Proc. Natl. Acad. Sci. U. S. A. 81:1287-1291.
24. Riberdy, J.M., and Cresswell, P. 1992. The antigen-processing mutant T2 suggests a role for MHC-linked genes in class II antigen presentation. J. Immunol. 148:2586-2590.
25. Denzin, L.K., Robbins, N.F., Carboy-Newcomb, C., and Cresswell, P. 1994. Assembly and intracellular transport of HLA-DM and correction of the class II antigen-processing in T2 cells. Immunity. 1:595-606.
26. Muller-Hermelink, H.K., and Marx, A. 1999. Pathological aspects of malignant and benign thymic disorders. Ann. Med. 31(Suppl. 2):5-14.
27. Laufer, T.M., Glimcher, L.H., and Lo, D. 1999. Using thymus anatomy to dissect T cell repertoire selection. Semin. Immunol. 11:65-70.
28. Kasai, M., Kominami, E., and Mizuochi, T. 1998. The antigen presentation pathway in medullary thymic epithelial cells, but not that in cortical thymic epithelial cells, conforms to the endocytic pathway. Eur. J. Immunol. 28:1867-1876.
29. Oukka, M., et al. 1997. Selectivity of the major histocompatibility complex class II presentation pathway of cortical thymic epithelial cell lines. Eur. J. Immunol. 27:855-859.
30. Kasai, M., Kropshofer, H., Vogt, A.B., Kominami, E., and Mizuochi, T. 2000. CLIP-derived self peptides bound to MHC class II molecules of medullary thymic epithelial cells differ from those of cortical thymic epithelial cells in their diversity, length, and C-terminal processing. Eur. J. Immunol. 30:3542-3551.
31. van Harn, S.M., et al. 1996. Human histocompatibiliry leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs. J. Exp. Med. 184:2019-2024.
32. Xing, R., Addington, A.K., and Mason, R.W. 1998. Quantification of cathepsins B and L in cells. Biochem. J. 332:499-505.
33. Vincent, A., Palace, J., and Hilton-Jones, D. 2001. Myasthenia gravis. Lancet. 357:2122-2128.
34. Bofill, M., et al. 1985. Microenvironments in the normal thymus and the thymus in myasthenia gravis. Am. J. Pathol. 119:462-473.
35. Wekerle, H., and Ketelsen, U.P. 1997. Intrathymic pathogenesis and dual genetic control of myasthenia gravis. Lancet. 1:678-680.
36. Buckley, C., Douek, D., Newsom-Davis, J., Vincent, A., and Willcox, N. 2001. Mature, long-lived CD4+ and CD8+ T cells are generated by the thymoma in myasthenia gravis. Ann. Neurol. 50:64-72.
37. Sempowski, G., et al. 2001. E£fect of thymectomy on human peripheral blood T cell pools in myasthenia gravis. J. Immunol. 166:2808-2817.
38. Strobel, P., et al. 2002. Paraneoplastic myasthenia gravis correlates with generation of mature naive CD4(+) T cells in thymomas. Blood. 100:159-166.
39. Melms, A., et al. 1988. Thymus in myasthenia gravis. Isolation of T-lymphocyte lines specific for the nicotinic acetylcholine receptor from thymuses of myasthenic patients. J. Clin. Invest. 81:902-908.
40. Bania, J., et al. 2003. Human cathepsin S, but not cathepsin L, degrades efficiently MHC class lI-associated invariant chain in nonprofessional APCs. Proc. Natl. Acad. Sci. U. S. A. 100:6664-6669.